Condition: CRC · Sponsor: Jin-hong Chen
This study is a single-arm, open-label, multicenter clinical study to evaluate the efficacy and safety of Candonilimab (AK104) combined with Regorafenib for the treatment of MSS colorectal liver metastasis. Candonilimab (AK104) is a humanized IgG1 bispecific antibody that targets PD-1 and CTLA-4.
This description comes directly from the study's public registry record.
Jinhong Chen, M.D · +8613801977742 · jinhongch@hotmail.com
Xiangyu Wang, M.D · +8618317086082 · wangxumed@163.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Soochow University | Suzhou, Jiangsu, China | Recruiting |
| Huashan Hospital | Shanghai, China | Recruiting |
| Shanghai Tenth People's Hospital | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06455254